{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:11:32Z","timestamp":1769584292372,"version":"3.49.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.numecd.2019.06.016","type":"journal-article","created":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T17:24:02Z","timestamp":1561397042000},"page":"1011-1022","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia \u2013 A systematic review and meta-analysis"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5095-8039","authenticated-orcid":false,"given":"Cheng-Wei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiao-Chin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Yi","family":"Shau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-Shun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man-Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung-Chih","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiao","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juey-Jen","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.numecd.2019.06.016_bib1","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/15257770802257952","article-title":"Inactivation of nitric oxide by uric acid","volume":"27","author":"Gersch","year":"2008","journal-title":"Nucleos Nucleot Nucleic Acids"},{"issue":"17","key":"10.1016\/j.numecd.2019.06.016_bib2","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.numecd.2019.06.016_bib3","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.2337\/db12-1814","article-title":"Sugar, uric acid, and the etiology of diabetes and obesity","volume":"62","author":"Johnson","year":"2013","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.numecd.2019.06.016_bib4","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/hy1101.092839","article-title":"Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism","volume":"38","author":"Mazzali","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.numecd.2019.06.016_bib5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.numecd.2018.10.001","article-title":"The dose-response effects of uric acid on the prevalence of metabolic syndrome and electrocardiographic left ventricular hypertrophy in healthy individuals","volume":"29","author":"Liu","year":"2019","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2019.06.016_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/milmed\/usy097","article-title":"Hyperuricemia is associated with a higher prevalence of metabolic syndrome in military individuals","author":"Liu","year":"2018","journal-title":"Mil Med"},{"issue":"12","key":"10.1016\/j.numecd.2019.06.016_bib7","doi-asserted-by":"crossref","first-page":"e114259","DOI":"10.1371\/journal.pone.0114259","article-title":"Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.numecd.2019.06.016_bib8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/acr.20065","article-title":"Hyperuricemia and coronary heart disease: a systematic review and meta-analysis","volume":"62","author":"Kim","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.numecd.2019.06.016_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1515\/cclm-2015-0523","article-title":"Hyperuricemia as risk factor for coronary heart disease incidence and mortality in the general population: a systematic review and meta-analysis","volume":"54","author":"Braga","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.numecd.2019.06.016_bib10","article-title":"Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.numecd.2019.06.016_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijcard.2016.10.025","article-title":"Relationship of serum uric acid and Killip class on mortality after acute ST-segment elevation myocardial infarction and primary percutaneous coronary intervention","volume":"226","author":"Liu","year":"2017","journal-title":"Int J Cardiol"},{"issue":"Suppl 2","key":"10.1016\/j.numecd.2019.06.016_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"issue":"33","key":"10.1016\/j.numecd.2019.06.016_bib13","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.numecd.2019.06.016_bib14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/0886022X.2018.1456463","article-title":"Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"40","author":"Liu","year":"2018","journal-title":"Ren Fail"},{"issue":"2","key":"10.1016\/j.numecd.2019.06.016_bib15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/07853890.2016.1243803","article-title":"Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis","volume":"49","author":"Qu","year":"2017","journal-title":"Ann Med"},{"issue":"1","key":"10.1016\/j.numecd.2019.06.016_bib16","first-page":"Cd008652","article-title":"Pharmacotherapy for hyperuricemia in hypertensive patients","volume":"4","author":"Gois","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.numecd.2019.06.016_bib17","first-page":"CD009460","article-title":"Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease","volume":"10","author":"Sampson","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.numecd.2019.06.016_bib18","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/rheumatology\/kex065","article-title":"Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis","volume":"56","author":"Zhang","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.numecd.2019.06.016_bib19","doi-asserted-by":"crossref","first-page":"8603164","DOI":"10.1155\/2016\/8603164","article-title":"Role of uric acid metabolism-related inflammation in the pathogenesis of metabolic syndrome components such as atherosclerosis and nonalcoholic steatohepatitis","volume":"2016","author":"Kushiyama","year":"2016","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.numecd.2019.06.016_bib20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2741\/3243","article-title":"Role of xanthine oxidoreductase in cardiac nitroso-redox imbalance","volume":"14","author":"Tziomalos","year":"2009","journal-title":"Front Biosci"},{"issue":"1","key":"10.1016\/j.numecd.2019.06.016_bib21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12872-018-0757-9","article-title":"Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Bredemeier","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"issue":"23","key":"10.1016\/j.numecd.2019.06.016_bib22","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.numecd.2019.06.016_bib23","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.numecd.2019.06.016_bib24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2350-12-118","article-title":"Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"12","author":"Somkrua","year":"2011","journal-title":"BMC Med Genet"},{"issue":"4","key":"10.1016\/j.numecd.2019.06.016_bib25","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/acr.21817","article-title":"Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.numecd.2019.06.016_bib26","doi-asserted-by":"crossref","first-page":"h4848","DOI":"10.1136\/bmj.h4848","article-title":"Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study","volume":"351","author":"Ko","year":"2015","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.numecd.2019.06.016_bib27","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40264-013-0084-0","article-title":"Allopurinol hypersensitivity: a systematic review of all published cases, 1950\u20132012","volume":"36","author":"Ramasamy","year":"2013","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.numecd.2019.06.016_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.numecd.2019.06.016_bib29","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jamainternmed.2015.3536","article-title":"Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan","volume":"175","author":"Yang","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.numecd.2019.06.016_bib30","article-title":"Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.numecd.2019.06.016_bib31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.numecd.2019.06.016_bib32","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.numecd.2019.06.016_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.2041-210x.2012.00250.x","article-title":"Review of alternative approaches to calculation of a confidence interval for the odds ratio of a 2 \u00d7 2 contingency table","volume":"4","author":"Ruxton","year":"2013","journal-title":"Methods Ecol Evol"},{"issue":"11","key":"10.1016\/j.numecd.2019.06.016_bib34","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.numecd.2019.06.016_bib35","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.numecd.2019.06.016_bib36","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"4 Suppl 2","key":"10.1016\/j.numecd.2019.06.016_bib37","first-page":"S44","volume":"17","author":"Kamatani","year":"2011","journal-title":"J Clin Rheumatol"},{"issue":"4 Suppl 2","key":"10.1016\/j.numecd.2019.06.016_bib38","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/RHU.0b013e31821d36cc","volume":"17","author":"Kamatani","year":"2011","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.numecd.2019.06.016_bib39","first-page":"52","article-title":"Comparative evaluation of efficacy and safety profile of febuxostat with allopurinol in patients with hyperuricemia and gout","volume":"2","author":"Kumar","year":"2013","journal-title":"Int J Pharma Med Biol Sci"},{"issue":"6","key":"10.1016\/j.numecd.2019.06.016_bib40","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/1756-185X.12266","article-title":"An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia","volume":"17","author":"Huang","year":"2014","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"10.1016\/j.numecd.2019.06.016_bib41","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/1756-185X.12648","article-title":"A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia","volume":"18","author":"Xu","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.numecd.2019.06.016_bib42","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijcme.2015.07.001","article-title":"Effects of febuxostat and allopurinol on the inflammation and cardiac function in chronic heart failure patients with hyperuricemia","volume":"8","author":"Nakagomi","year":"2015","journal-title":"IJC Metab Endocr"},{"issue":"6","key":"10.1016\/j.numecd.2019.06.016_bib43","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1007\/s10157-015-1095-1","article-title":"Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial","volume":"19","author":"Tanaka","year":"2015","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"10.1016\/j.numecd.2019.06.016_bib44","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3109\/03009742.2015.1099729","article-title":"Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study","volume":"45","author":"Yu","year":"2016","journal-title":"Scand J Rheumatol"},{"issue":"13","key":"10.1016\/j.numecd.2019.06.016_bib45","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.numecd.2019.06.016_bib46","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jbspin.2015.07.011","article-title":"Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment","volume":"83","author":"Bardin","year":"2016","journal-title":"Jt Bone Spine"},{"issue":"8","key":"10.1016\/j.numecd.2019.06.016_bib47","first-page":"393","article-title":"Major cardiovascular events in patients with gout and associated cardiovascular disease or heart failure and chronic kidney disease initiating a xanthine oxidase inhibitor","volume":"10","author":"Foody","year":"2017","journal-title":"Am Health Drug Benefits"},{"issue":"4","key":"10.1016\/j.numecd.2019.06.016_bib48","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3329\/bjms.v10i4.7522","article-title":"Comparison between Allopurinol and Febuxostat in management of gout patients - a prospective study","volume":"10","author":"Singal","year":"2011","journal-title":"Bangladesh J Med Sci"},{"issue":"1","key":"10.1016\/j.numecd.2019.06.016_bib49","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jjcc.2016.02.015","article-title":"Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia","volume":"69","author":"Kojima","year":"2017","journal-title":"J Cardiol"},{"issue":"5","key":"10.1016\/j.numecd.2019.06.016_bib50","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1536\/ihj.17-560","article-title":"Randomized trial of effect of urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia (LEAF-CHF)","volume":"59","author":"Yokota","year":"2018","journal-title":"Int Heart J"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475319302455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475319302455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:10:39Z","timestamp":1760544639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475319302455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0939475319302455"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2019.06.016","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia \u2013 A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2019.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}